NeOnc Technologies Forms $50 Million Strategic Partnership with Quazar Investment to Expand in the MENA Region.

Jul 10, 2025•7 days ago

Contract Type

partnership

CalabasasBiotechnology

Description

NeOnc Technologies has received approval from its Board of Directors for a $50 million equity investment to establish a partnership with Quazar Investment. This milestone marks significant progress in their efforts to expand operations in the MENA region and enhance clinical trial capabilities.

Company Information

Company

NeOnc Technologies

Location

23975 PARK SORRENTO

Calabasas, California, United States

About

NeOnc Technologies is a publicly traded, clinical-stage biopharmaceutical company developing innovative therapies for brain and central nervous system cancers. Its lead programs—NEO100-01, NEO100-02, NEO100-03, and NEO212—utilize proprietary formulations to bypass the blood-brain barrier and target malignancies with precision. The company’s IP portfolio includes 176 patents worldwide, reflecting a broad platform with strong commercialization potential.

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

NeOnc Technologies Forms $50 Million Strategic Partnership with Quazar Investment to Expand in the MENA Region.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Agreement Insights

Related People

Company Information